GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 7,470,000 shares, a decrease of 5.8% from the December 15th total of 7,930,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 5.5 days. Currently, 8.6% of the company’s shares are sold short.

GoodRx Trading Up 3.4 %

Shares of NASDAQ:GDRX opened at $4.57 on Monday. GoodRx has a 52-week low of $4.09 and a 52-week high of $9.26. The company has a 50-day simple moving average of $4.59 and a 200 day simple moving average of $6.43. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market capitalization of $1.74 billion, a P/E ratio of -152.33, a price-to-earnings-growth ratio of 2.30 and a beta of 1.27.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GDRX shares. Citigroup dropped their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Barclays decreased their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Finally, Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.38.

Hedge Funds Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. Sugar Maple Asset Management LLC bought a new stake in shares of GoodRx in the fourth quarter valued at about $122,000. Fortem Financial Group LLC increased its stake in shares of GoodRx by 7.2% in the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after purchasing an additional 7,996 shares during the last quarter. JPMorgan Chase & Co. raised its stake in GoodRx by 358.7% during the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after acquiring an additional 18,997 shares in the last quarter. Franklin Resources Inc. bought a new position in GoodRx in the 3rd quarter valued at approximately $5,675,000. Finally, Sanctuary Advisors LLC bought a new stake in GoodRx during the 3rd quarter worth $85,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.